Davita Inc vs iShares 3 7 Year Treasury Bond ETF — how do they compare? Davita Inc trades at $178.69 (market cap $11.38B), while iShares 3 7 Year Treasury Bond ETF trades at $116.54. The key difference: Davita Inc is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| DVA | IEI | |
|---|---|---|
Market Cap | $11.38B | — |
Sector | Health | Fixed Income |
52-Week High | $240.96 | $120.72 |
52-Week Low | $103.87 | $116.16 |
Enterprise Value | $24.10B | — |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.69, down slightly by 0.04% over the past day. The stock shows strong fundamental performance with consistent earnings beats in recent quarters, including Q2 2026 EPS of $4.02 versus $3.88 expected (Zacks Investment Research, 2026-08-04). However, technical indicators signal a bearish trend, with the price near key support at $182. Revenue growth remains steady, climbing to $13.64 billion in 2025, though net income margin dipped to 5.47%.
The outlook is mixed; analyst consensus leans bullish with a $232.25 price target (MarketBeat, 2026-08-05), but risks include reimbursement pressure and high debt levels. Investment appeal hinges on execution against guidance amid payer-mix challenges, with the current valuation offering potential upside if operational trends stabilize.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.565, up 0.27% today, with technical indicators showing a bearish trend from moving averages and neutral oscillators. Recent news highlights institutional activity, including Bank of America increasing its stake by 39.7% in the latest quarter (Defense World, 2026-08-01). The fund maintains a conservative profile with regular dividend distributions, appealing to income-focused investors amid volatile bond markets.
The outlook for IEI is cautious due to rising Treasury yields and inflation concerns, posing risks from potential Fed rate hikes. However, its government backing and lower volatility offer stability for risk-averse portfolios, with income generation from dividends remaining a key attraction despite macroeconomic headwinds.
Trailing returns across standard periods
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →